Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Home Instillation of UGN-102 in LG-IR-NMIBC
NCT05136898Phase 3Completed
- Sponsor
- UroGen Pharma
- Start
- Nov 2021
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of mitapivat in Non-muscle-invasive bladder cancer (NMIBC), sponsored by UroGen Pharma. Started Nov 2021; status: completed.
02
Drugs
mitapivat
03
Conditions
Non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT05136898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05136898.